Ambys Medicines
Charles Homcy, M.D., partner at Third Rock Ventures, focuses on the formation of companies discovering and developing novel therapeutic approaches. He has significant experience building and leading successful biotech companies and has played an integral role in the launching and building of several portfolio companies, including Global Blood Therapeutics, MyoKardia and Pliant.
Prior to Third Rock, Charles co-founded Portola Pharmaceuticals and served as president and chief executive officer, and now serves on its board of directors. Earlier, he served as president of research and development at Millennium, following Millennium’s acquisition of COR Therapeutics in 2002. He joined COR in 1995 as executive vice president of research and development and served as a director of the company from 1998 to 2002. He has been a clinical professor of medicine at the UCSF Medical School and attending physician at the San Francisco VA Hospital since 1997. Charles was previously president of the Medical Research Division of American Cyanamid-Lederle Laboratories, a division of Wyeth.
Charles holds an A.B. and M.D. from Johns Hopkins University, where he presently serves on the board of trustees.
This person is not in the org chart
This person is not in any offices
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today.